The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways

British Journal of Pharmacology

Volumn 131, Issue 8, 2000, Pages 1607-1618

  Schmidt, Dunja T ^a   Watson, Nikki ^b   Dent, Gordon ^c   Rühlmann, Elke ^a   Branscheid, Detlev ^d   Magnussen, Helgo ^d   Rabe, Klaus F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROCHE BIOSCIENCE   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Allergen; Bronchoconstriction; Bronchus, human; Passive sensitization; Phosphodiesterase inhibitors; Phosphodiesterase isoenzymes

Indexed keywords

ALLERGEN; ISOBUTYLMETHYLXANTHINE; LEUKOTRIENE C4; MOTAPIZONE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; ROLIPRAM; THEOPHYLLINE; ZARDAVERINE;

AIRWAY RESISTANCE; ALLERGIC REACTION; ANTIBODY SPECIFICITY; ARTICLE; BREATHING MUSCLE; BRONCHOSPASM; BRONCHUS REACTIVITY; BRONCHUS TONE; DRUG EFFECT; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MEDIATOR RELEASE; PRIORITY JOURNAL; SENSITIZATION; SMOOTH MUSCLE CONTRACTILITY;

EID: 0034531342     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703725     Document Type: Article

References (52)

1. Effect of isoenzyme-selective inhibitors of phosphodiesterase (PDE) on human lung mast cells (HLMC)
2. Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents: The synthesis and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues
3. Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors
4. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
5. Phosphodiesterase inhibition and theophylline
6. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: Pharmacological evidence obtained with tissues from asthmatic and nonasthmatic subjects
7. Further evidence that leukotrienes are the major mediators of allergic constriction in human bronchi
8. Recent progress in understanding the hormonal regulation of phosphodiesterases
9. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro
10. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus
11. Asthma, adenosine, mast cells and theophylline
12. Role of adenosine in the pathogenesis of bronchial asthma
13. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors
14. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: Interaction with the beta adrenoceptor agonist albuterol
15. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi
16. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase
17. Nomenclature and classification of purinoceptors
18. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors
19. + T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2
20. 2-adrenoceptor agonists on anti-IgE-induced contraction and smooth muscle reactivity in human airways
21. Endothelin-induced contraction and mediator release in human bronchus
22. Ketamine inhibits agonist-induced cAMP accumulation increase in human airway smooth muscle cells
23. Purines and sensory neuropeptides in human asthma
24. Theophylline: Anti-inflammatory effects
25. Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods
26. LY18665, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments
27. Bronchodilator effects of theophylline preparations and aerosol fenoterol in stable asthma
28. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics
29. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients
30. Global strategy for asthma management and prevention
31. Guidelines for the diagnoses and management of asthma
32. 4, methacholine and histamine in normal and asthmatic subjects
33. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction
34. Arachidonic acid metabolism in purified human lung mast cells
35. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization
36. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
37. Characterization of inflammatory mediator release from purified human lung mast cells
38. 4
39. Zardaverine: A cyclic AMP specific PDE III/IV inhibitor
40. i
41. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
42. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
43. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
44. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods
45. Molecular targets for novel anti-asthma agents
46. Ariflo™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From the concept to the clinic
47. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle
48. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes
49. Theophylline: An immunomodulatory role in asthma
50. Role of IgE in hyperresponsiveness induced by passive sensitization of human airways
51. Theophylline in asthma
52. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function